A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

CCX282-B, also called vercirnon, is a specific, orally-administered chemokine receptor CCR9 antagonist that regulates migration and activation of inflammatory cells in the intestine. This randomized, placebo-controlled trial was conducted to evaluate the safety and efficacy of CCX282-B in 436 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshav, Satish, Vaňásek, Tomáš, Niv, Yaron, Petryka, Robert, Howaldt, Stephanie, Bafutto, Mauro, Rácz, István, Hetzel, David, Nielsen, Ole Haagen, Vermeire, Séverine, Reinisch, Walter, Karlén, Per, Schreiber, Stefan, Schall, Thomas J., Bekker, Pirow
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603920/
https://www.ncbi.nlm.nih.gov/pubmed/23527300
http://dx.doi.org/10.1371/journal.pone.0060094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603920/
https://www.ncbi.nlm.nih.gov/pubmed/23527300
http://dx.doi.org/10.1371/journal.pone.0060094

Ejemplares similares